In its Q2 2026 investor letter, Clearbridge Small Cap Growth Strategy highlighted Insmed Incorporated (NASDAQ:INSM).
Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company focusing on developing therapies for patients with serious and rare diseases
On July 23, 2026, Insmed Incorporated (NASDAQ:INSM) closed at $107.41 per share, reflecting a market capitalization of $23.28 billion. Insmed Incorporated (NASDAQ:INSM) posted a one-month return of 3.06%, and its shares gained 2.50% over the past 52 weeks. Clearbridge Small Cap Growth Strategy stated the following regarding Insmed Incorporated (NASDAQ:INSM) in its Q2 2026 investor update: “In health care, weakness was concentrated in a few idiosyncratic holdings, despite a strong quarter for biotech.
Long-standing biotech holding Insmed Incorporated (NASDAQ:INSM) gave up some of the prior year’s strength driven by concerns around the pace of key drug Brinsupri’s launch. We remain confident in the meaningful long-term peak sales potential and believe recent weakness has been overly punitive.” Insmed Incorporated (NASDAQ:INSM) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 67 hedge fund portfolios held Insmed Incorporated (NASDAQ:INSM) at the end of the first quarter, compared to 75 in the previous quarter.